Published in Lancet on August 13, 1983
Serotypes, hemolysin production, and receptor recognition of Escherichia coli strains associated with neonatal sepsis and meningitis. Infect Immun (1985) 4.01
Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev (2000) 3.69
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak. N Engl J Med (2016) 3.47
Molecular characterization and expression in Escherichia coli of the gene complex encoding the polysaccharide capsule of Neisseria meningitidis group B. Proc Natl Acad Sci U S A (1989) 2.83
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Meningococcal carriage and disease--population biology and evolution. Vaccine (2009) 2.62
Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun (2004) 2.44
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev (1998) 2.06
Genetic analysis of chromosomal mutations in the polysialic acid gene cluster of Escherichia coli K1. J Bacteriol (1989) 1.97
Sialylation of lipooligosaccharide cores affects immunogenicity and serum resistance of Campylobacter jejuni. Infect Immun (2000) 1.95
Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine (2013) 1.94
Use of prokaryotic-derived probes to identify poly(sialic acid) in neonatal neuronal membranes. Proc Natl Acad Sci U S A (1984) 1.92
Guillain-Barré syndrome and Campylobacter jejuni: a serological study. Br Med J (Clin Res Ed) (1984) 1.90
Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins. Infect Immun (1990) 1.87
The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun (1998) 1.78
Identification of two genes, kpsM and kpsT, in region 3 of the polysialic acid gene cluster of Escherichia coli K1. J Bacteriol (1991) 1.77
Pathogenicity island evaluation in Escherichia coli K1 by crossing with laboratory strain K-12. Infect Immun (1996) 1.75
Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev (2010) 1.70
The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun (2005) 1.68
Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun (2008) 1.66
Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect Immun (2008) 1.61
Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect Immun (1989) 1.59
Review of meningococcal group B vaccines. Clin Infect Dis (2010) 1.58
Impaired colonization by and full invasiveness of Escherichia coli K1 bearing a site-directed mutation in the type 1 pilin gene. Infect Immun (1990) 1.57
Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines (2009) 1.54
Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology (2009) 1.54
Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev (2006) 1.53
Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infect Immun (1990) 1.52
Expression of sialic acid and polysialic acid in serogroup B Neisseria meningitidis: divergent transcription of biosynthesis and transport operons through a common promoter region. J Bacteriol (1996) 1.50
Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun (1998) 1.46
Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun (2007) 1.44
A monoclonal antibody against meningococcus group B polysaccharides distinguishes embryonic from adult N-CAM. J Cell Biol (1986) 1.42
Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Infect Immun (1996) 1.38
Identification of a genetic locus involved in the biosynthesis of N-acetyl-D-mannosamine, a precursor of the (alpha 2-->8)-linked polysialic acid capsule of serogroup B Neisseria meningitidis. J Bacteriol (1994) 1.33
Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide. J Exp Med (1989) 1.33
Translocation of capsular polysaccharides in pathogenic strains of Escherichia coli requires a 60-kilodalton periplasmic protein. J Bacteriol (1987) 1.31
Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol (2007) 1.30
Type-specific contributions to chromosome size differences in Escherichia coli. Infect Immun (1999) 1.29
Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun (2011) 1.29
Molecular characterization of the 98-kilodalton iron-regulated outer membrane protein of Neisseria meningitidis. Infect Immun (1993) 1.29
Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev (1993) 1.26
Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci U S A (1991) 1.22
Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol (2008) 1.22
N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J Exp Med (1987) 1.21
Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun (2002) 1.21
Meningococcal disease and the complement system. Virulence (2013) 1.19
An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential. PLoS Pathog (2010) 1.19
Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide. Infect Immun (1985) 1.19
Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect Immun (1999) 1.17
The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog (2012) 1.17
Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun (2005) 1.17
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun (2006) 1.15
Nucleotide sequence and genetic analysis of the neuD and neuB genes in region 2 of the polysialic acid gene cluster of Escherichia coli K1. J Bacteriol (1995) 1.15
Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect Immun (1999) 1.15
Analysis of Neisseria meningitidis class 3 outer membrane protein gene variable regions and type identification using genetic techniques. Infect Immun (1995) 1.13
Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. MBio (2014) 1.13
Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1. Infect Immun (1985) 1.11
Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect Immun (2006) 1.10
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog (2012) 1.10
Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect Immun (2011) 1.06
Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis. J Exp Med (1992) 1.06
The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun (2013) 1.06
Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules. FEMS Microbiol Rev (2014) 1.05
Bexsero® chronicle. Pathog Glob Health (2014) 1.05
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev (2013) 1.05
Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect Immun (2005) 1.05
Bacterial outer membrane vesicles in disease and preventive medicine. Semin Immunopathol (2010) 1.05
Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration. FEMS Immunol Med Microbiol (2010) 1.04
Effect of Tamm-Horsfall urinary glycoprotein on phagocytosis and killing of type I-fimbriated Escherichia coli. Infect Immun (1986) 1.02
Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines. Microbiology (2008) 1.01
Association of meningococcal serogroups with the course of disease in the Netherlands, 1959-83. Bull World Health Organ (1987) 1.01
Nucleotide sequence and mutational analysis of the gene encoding KpsD, a periplasmic protein involved in transport of polysialic acid in Escherichia coli K1. J Bacteriol (1994) 1.01
Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates. Infect Immun (1991) 1.00
Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years. J Clin Microbiol (2014) 1.00
The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis? Philos Trans R Soc Lond B Biol Sci (2013) 0.99
Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin Infect Dis (2011) 0.98
Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol (2010) 0.98
Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses? Clin Vaccine Immunol (2013) 0.98
Meningococcal infections in the Province of Québec, Canada, during the period 1991 to 1992. J Clin Microbiol (1995) 0.97
A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol (2011) 0.97
Deletion of fetA gene sequences in serogroup B and C Neisseria meningitidis isolates. J Clin Microbiol (2007) 0.97
Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain. Infect Immun (1995) 0.97
New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers. Indian J Med Res (2013) 0.96
Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease. Clin Diagn Lab Immunol (1995) 0.96
Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun (2003) 0.96
Autoimmunity: a decision theory model. J Clin Pathol (1987) 0.96
DNA probes for K-antigen (capsule) typing of Escherichia coli. J Clin Microbiol (1988) 0.95
Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. Infect Immun (2006) 0.95
Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens. Postgrad Med J (2001) 0.95
Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates. Infect Immun (2013) 0.95
Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect Immun (1993) 0.95
Identity between polysaccharide antigens of Moraxella nonliquefaciens, group B Neisseria meningitidis, and Escherichia coli K1 (non-O acetylated). Infect Immun (1991) 0.94
Current status of meningococcal group B vaccine candidates: capsular or noncapsular? Clin Microbiol Rev (1994) 0.94
The epidemiology of meningococcal disease in Latin America 1945-2010: an unpredictable and changing landscape. Epidemiol Infect (2012) 0.94
Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect Immun (2009) 0.94
Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol (2014) 0.93
Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against neisseria meningitidis groups B and C. J Immunol (2009) 0.93
Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med (2001) 10.56
Lipopolysaccharide heterogeneity in Salmonella typhimurium analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Eur J Biochem (1980) 8.05
Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet (1988) 7.59
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med (1992) 5.65
Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J (2000) 4.87
The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis (1983) 4.05
Serotypes, hemolysin production, and receptor recognition of Escherichia coli strains associated with neonatal sepsis and meningitis. Infect Immun (1985) 4.01
F + , Hfr, and F' strains of Salmonella typhimurium and Salmonella abony. Bacteriol Rev (1972) 3.73
Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax (2001) 3.72
P-fimbriated clones among uropathogenic Escherichia coli strains. Infect Immun (1984) 3.50
Mannose-resistant haemagglutination and P antigen recognition are characteristic of Escherichia coli causing primary pyelonephritis. Lancet (1982) 3.39
Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax (2001) 3.38
Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med (1984) 3.37
Viruses and bacteria in the etiology of the common cold. J Clin Microbiol (1998) 3.24
Escherichia coli fimbriae recognizing sialyl galactosides. J Bacteriol (1984) 3.16
Characterization of the lipopolysaccharide from the polymyxin-resistant pmrA mutants of Salmonella typhimurium. FEBS Lett (1981) 2.91
A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med (1990) 2.90
Escherichia coli strains binding neuraminyl alpha 2-3 galactosides. Biochem Biophys Res Commun (1983) 2.87
Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis (1991) 2.83
Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis (1977) 2.79
Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation (1993) 2.70
Diagnosis of bacteremic pneumococcal pneumonia by amplification of pneumolysin gene fragment in serum. J Infect Dis (1995) 2.62
Identification of the O-linked sialyloligosaccharides of glycophorin A as the erythrocyte receptors for S-fimbriated Escherichia coli. Infect Immun (1986) 2.62
An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol (1987) 2.54
Immunization with major outer membrane proteins in experimental salmonellosis of mice. Infect Immun (1979) 2.53
Occurrence of alpha 2-8 linked polysialosyl units in a neural cell adhesion molecule. Biochem Biophys Res Commun (1983) 2.48
Effect of polymyxin on the ultrastructure of the outer membrane of wild-type and polymyxin-resistant strain of Salmonella. J Bacteriol (1976) 2.43
Enterobacterial common antigen. Bacteriol Rev (1976) 2.41
Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development. Microb Pathog (1987) 2.40
Probing of the receptor-binding sites of the H1 and H3 influenza A and influenza B virus hemagglutinins by synthetic and natural sialosides. Virology (1993) 2.27
The genus-specific antigen of Chlamydia: resemblance to the lipopolysaccharide of enteric bacteria. Science (1983) 2.22
Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine (1989) 2.20
Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis (1996) 2.15
Aetiology of community-acquired pneumonia in children treated in hospital. Eur J Pediatr (1993) 2.10
Occurrence of unique polysialosyl carbohydrate units in glycoproteins of developing brain. J Biol Chem (1982) 2.09
Cross-reactivity between Chlamydiazyme and Acinetobacter strains. N Engl J Med (1986) 2.09
Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg (2001) 2.08
Bacteriophage-resistant mutants of Salmonella typhimurium deficient in two major outer membrane proteins. J Bacteriol (1976) 2.02
Measurement of antibody responses to pneumolysin--a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect (1989) 2.00
Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet (1975) 1.97
Use of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in Pakistan for surveillance for antimicrobial resistance. Pediatr Infect Dis J (1993) 1.95
A new gene cluster rfe concerned with the biosynthesis of Salmonella lipopolysaccharide. J Gen Microbiol (1970) 1.91
Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis (1999) 1.90
Epidemiology of invasive pneumococcal infections in children in Finland. JAMA (1992) 1.90
Risk factors for pneumonia in the elderly. Am J Med (1994) 1.89
The role of IFN-gamma in murine Salmonella typhimurium infection. Microb Pathog (1990) 1.84
The structural basis of the different affinities of two types of acidic N-glycosidic glycopeptides for concanavalin A--sepharose. FEBS Lett (1976) 1.84
Genetic determination of the O antigens of Salmonella groups B (4,5,12) and C1(6,7). J Bacteriol (1966) 1.81
Lipopolysaccharide nomenclature--past, present, and future. J Bacteriol (1986) 1.80
Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis (2001) 1.80
Inheritance of the O antigens of Salmonella groups B and D. J Gen Microbiol (1965) 1.79
Infections, inflammation, and the risk of coronary heart disease. Circulation (2000) 1.77
New Salmonella typhimurium mutants with altered outer membrane permeability. J Bacteriol (1984) 1.76
Pneumolysin PCR-based diagnosis of invasive pneumococcal infection in children. J Clin Microbiol (1999) 1.75
Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol (1997) 1.74
Comparison of four different sampling methods for detecting pharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children. J Clin Microbiol (1997) 1.74
Cleavage of the polysialosyl units of brain glycoproteins by a bacteriophage endosialidase. Involvement of a long oligosaccharide segment in molecular interactions of polysialic acid. J Biol Chem (1985) 1.71
Comparison of PCR assay with bacterial culture for detecting Streptococcus pneumoniae in middle ear fluid of children with acute otitis media. J Clin Microbiol (1994) 1.71
Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J (1990) 1.69
A novel virulence-associated cell surface structure composed of 47-kd protein subunits in Yersinia enterocolitica. EMBO J (1985) 1.68
Etiology of acute lower respiratory tract infections in Gambian children: I. Acute lower respiratory tract infections in infants presenting at the hospital. Pediatr Infect Dis J (1991) 1.66
Polyacrylamide gel electrophoresis of the capsular polysaccharides of Escherichia coli K1 and other bacteria. J Bacteriol (1988) 1.66
Basement membrane carbohydrate as a target for bacterial adhesion: binding of type I fimbriae of Salmonella enterica and Escherichia coli to laminin. Mol Microbiol (1993) 1.66
Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics (1984) 1.65
Genetic aspects of biosynthesis and structure of Salmonella somatic polysaccharide. Ann N Y Acad Sci (1966) 1.64
An outer membrane-disorganizing peptide PMBN sensitizes E. coli strains to serum bactericidal action. J Immunol (1984) 1.62
Mutants defective in the 33K outer membrane protein of Salmonella typhimurium. J Bacteriol (1979) 1.60
The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods. Scand J Infect Dis (1981) 1.59
Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J (1998) 1.59
Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay. Infect Immun (1982) 1.58
Genetic determination of enzymes synthesizing O-specific sugars of Salmonella lipopolysaccharides. J Bacteriol (1966) 1.58
Etiology of acute lower respiratory tract infections in Gambian children: II. Acute lower respiratory tract infection in children ages one to nine years presenting at the hospital. Pediatr Infect Dis J (1991) 1.57
Role of O-antigen (lipopolysaccharide) factors in the virulence of Salmonella. J Infect Dis (1973) 1.57
Subtyping of common pediatric pneumococcal serotypes from invasive disease and pharyngeal carriage in Finland. J Infect Dis (1996) 1.54
Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis (1980) 1.53
Occurrence of type-1C fimbriae on Escherichia coli strains isolated from human extraintestinal infections. J Gen Microbiol (1985) 1.53
Participation of lipopolysaccharide genes in the determination of the enterobacterial common antigen: analysis of R mutants of Salmonella minnesota. J Bacteriol (1974) 1.52
Antibody levels achieved in infants by course of Haemophilus influenzae type B polysaccharide/diphtheria toxoid conjugate vaccine. Lancet (1985) 1.52
Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J (2000) 1.50
Neural surface antigens during nervous system development. Cold Spring Harb Symp Quant Biol (1983) 1.50
Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med (1997) 1.50
Variability of penicillin-binding proteins from penicillin-sensitive Streptococcus pneumoniae. J Infect Dis (1991) 1.48
The latex agglutination test for the diagnosis of meningococcal and haemophilus influenzae meningitis. Scand J Infect Dis (1977) 1.47
Protein K: a new major outer membrane protein found in encapsulated Escherichia coli. J Bacteriol (1979) 1.47
Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis (1995) 1.47
Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis (2001) 1.47
Binding of Escherichia coli S fimbriae to human kidney epithelium. Infect Immun (1986) 1.46
Differential expression of mouse neural cell-adhesion molecule (N-CAM) mRNA species during brain development and in neural cell lines. J Neurosci (1986) 1.46
Phagocytosis of bacteria by macrophages: changing the carbohydrate of lipopolysaccharide alters interaction with complement and macrophages. J Immunol (1982) 1.45